What Degron Therapeutics does

Degron Therapeutics is a clinical-stage biotechnology company developing a new class of small molecule molecular glue degrader (MGD) drugs against previously undruggable disease targets. Its core offering is the proprietary GlueXplorer® MGD discovery platform, which combines a biology-backed compound library of over 10,000 structurally differentiated MGD compounds built on novel scaffold chemistry (deliberately distinct from IMiD cores such as lenalidomide), comprehensive screening and validation systems, and AI/machine learning analysis of large proprietary compound-induced proximity and degradation data sets. The platform enables rational rather than serendipitous MGD design, opening access to targets and IP positions that IMiD-based programs cannot reach.

The company's lead product is DEG6498, a first-in-class orally bioavailable molecular glue degrader that induces the interaction between the E3 ubiquitin ligase component cereblon (CRBN) and the RNA-binding protein HuR (ELAVL1), leading to targeted HuR degradation. DEG6498 received FDA IND clearance in January 2025 and entered Phase 1 dose escalation for advanced solid tumors in late 2025. The pipeline also includes a WEE1 molecular glue degrader (preclinical candidate selection targeted for 1H 2025) and multiple Inflammation & Immunology programs approaching IND-stage development, with HuR biology applied to pancreatitis, rheumatoid arthritis, and neuroinflammation indications. A Nature publication in mid-2026 disclosed the mechanism of HuR molecular glue degraders in BRAF-mutant tumors, providing peer-reviewed mechanistic validation.

Degron operates a licensing/partnership-driven business model rather than direct commercialization. Revenue mechanics are structured around upfronts, clinical and commercial milestones, and royalties from pharma partners, including a joint development collaboration with MSD R&D (China) for oncology candidates and an ongoing partnership with Takeda. The company is dual-headquartered in Shanghai (Pudong) with a US R&D office in San Diego, was founded in 2021, has grown to 101-250 employees, and has raised approximately $95 million in total capital across its Series A ($22M initial plus follow-ons) and a $40M Series A extension in May 2026. Co-founders Lily Zou (CEO; ex-Fosun Pharma USA CEO, MIT Sloan MBA) and Yong Cang (CSO; ShanghaiTech University professor, ex-Stanford Burnham Prebys) lead the company alongside CMO/CDO Xiaobing Qian, VP Chemistry Zhongdong Zhao (ex-Gilead), and Chemistry Advisor Mark Ashwell (ex-ArQule/Nimbus/Wyeth).

Name

Degron Therapeutics

Legal name

Degron Therapeutics Co.

Website

https://degrontx.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

101–250 employees

Short description

Degron Therapeutics is a clinical-stage biotechnology company developing first-in-class molecular glue degrader (MGD) drugs for cancer and inflammatory diseases using its proprietary GlueXplorer® discovery platform, with lead asset DEG6498 in Phase 1 for solid tumors.

Ownership category

akta.pro rank

Product category

Targeted Protein Degradation Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Cheminformatics & Molecular Modeling / CADD (HLAGAJAE)

Keywords

• Molecular glue degraders
• Targeted protein degradation
• Oncology drug discovery
• Small molecule therapeutics
• Protein degradation platform

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Drug Development and Commercialization: Degron Therapeutics is a clinical-stage biotechnology company developing small molecule molecular glue degrader drugs. Revenue will be generated through clinical development milestones, potential partnership deals with pharmaceutical companies, and eventual drug commercialization. The company has entered joint development collaborations and maintains partnerships with pharmaceutical companies including Takeda.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Degron Therapeutics is a clinical-stage biotechnology company developing a new class of small molecule molecular glue degrader (MGD) drugs using GlueXplorer®, its proprietary drug discovery platform. The platform combines a structurally differentiated compound library of over 10,000 MGD compounds, comprehensive screening and validation systems, and large proprietary proximity/degradation data sets applied through AI and machine learning to rationally design degraders against historically undruggable disease targets. The lead program DEG6498 is a first-in-class HuR (ELAVL1) molecular glue degrader currently in Phase 1 clinical trials for advanced solid tumors, supported by additional WEE1 and immunology programs.

Product overview

Degron Therapeutics is a clinical-stage biotechnology company developing a new class of small molecule molecular glue degrader (MGD) drugs. The company's core offering consists of the GlueXplorer® platform, a proprietary drug discovery platform employing molecular glue technology, AI, and advanced screening methods to create novel MGDs against historically intractable disease targets. The platform includes a rapidly expanding structurally differentiated compound library of over 10,000 MGD compounds. The lead product, DEG6498, is a first-in-class HuR molecular glue degrader currently in Phase 1 clinical trials for advanced solid tumors. The pipeline also includes WEE1 molecular glue degrader and multiple immunology programs.

Differentiator

Problem solved

Functional benefit

Brands

• GlueXplorer®: Proprietary molecular glue-based targeted protein degradation drug discovery platform that enables rational design of MGDs with over 10,000 structurally differentiated compounds.

Products and services

• GlueXplorer® MGD Discovery Platform Proprietary molecular glue-based targeted protein degradation drug discovery platform with a biology-backed glue library of >10,000 structurally differentiated MGD compounds, comprehensive screening/validation systems, and large proprietary compound-induced proximity and degradation data sets used with AI/Machine learning to discover novel MGDs against intractable disease targets. Offered to pharmaceutical industry partners for MGD discovery collaborations.
• DEG6498 First-in-class, potent, orally bioavailable small molecule molecular glue degrader that induces interaction between the E3 ubiquitin ligase component cereblon (CRBN) and HuR (ELAVL1), leading to targeted degradation of the HuR protein. In Phase 1 clinical development for advanced solid tumors, with potential application in cancer, inflammation, and metabolic disorders where HuR plays a critical role. Developed for oncology patients with solid tumors driven by HuR overexpression or cytoplasmic enrichment.
• WEE1 Molecular Glue Degrader Program First-in-class WEE1 molecular glue degrader program with a differentiated mechanism of action versus conventional WEE1 inhibitors. Targets WEE1 kinase, which phosphorylates and inhibits CDK1 and CDK2 to coordinate cell cycle arrest with DNA damage response. Advancing toward preclinical development candidate selection.
• Inflammation and Immunology Programs Multiple discovery-stage immunology programs targeting validated disease targets where HuR plays a critical role in disease progression, including pancreatitis, rheumatoid arthritis, and neuroinflammation. Programs are approaching IND-stage development using the GlueXplorer platform and MGD chemistry.

Quantifiable outcome

• FDA IND clearance received January 2025 for DEG6498 in solid tumors
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature3 records

Partnerships

Two partnerships are on record, tiered core and minor.

• MSD R&D (China) Co., Ltd.coreStrategic or Co-development Partner · 21 May 2026Degron Therapeutics entered into a joint development collaboration agreement with MSD R&D (China) to jointly advance the clinical development of molecular glue candidates in oncology. This partnership supports the advancement of the lead HuR molecular glue degrader program.
• TakedaminorStrategic or Co-development PartnerDegron maintains partnerships with pharmaceutical companies including Takeda for molecular glue-based targeted protein degradation collaboration.

Scale indicators6 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• C4 Therapeutics: Clinical-stage company developing small molecule degraders (TPD) including both cereblon- and DCAF15-based molecular glue degraders. Comparable discovery approach and oncology focus with pharma partnerships (Biogen, Merck KGaA, Calico).
• Plexium: Emerging biotech developing molecular glue degraders and proximity-based therapeutics leveraging AI/ML-enabled discovery. Comparable platform-approach using induced-proximity chemistry against previously undruggable targets.
• Foghorn Therapeutics: Clinical-stage biotech developing medicines targeting the chromatin regulatory system, including a molecular glue degrader program against BRD9. Comparable platform-based modality targeting historically undruggable proteins in oncology.
• Monte Rosa Therapeutics: Clinical-stage biotechnology company developing molecular glue degraders to eliminate disease-driving proteins. Most direct peer to Degron given identical MGD therapeutic modality and platform-based discovery approach.
• Arvinas: Pioneer in targeted protein degradation with both PROTAC and expanding molecular glue degrader programs in oncology (e.g., vepdegestrant with Pfizer). Closely comparable therapeutic modality, pipeline depth, and partnership-driven strategy.
• Nurix Therapeutics: Clinical-stage biotech developing targeted protein degradation medicines (both degraders and deubiquitinase modulators) in oncology and immunology. Has established major pharma collaborations (Sanofi, Gilead, Pfizer), comparable in partnership model.
• Cullgen: Clinical-stage precision medicine company developing targeted protein degraders and small molecule therapeutics in oncology. Comparable modality focus and Asian/US operational footprint akin to Degron's Shanghai-San Diego structure.
• Kymera Therapeutics: Clinical-stage biotech developing targeted protein degraders including molecular glue degraders across oncology and immunology. Highly comparable platform-and-pipeline structure with multiple clinical assets and major pharma collaborations (e.g., Sanofi, Vertex).

Emerging players

• Neomorph (Novartis): Pre-clinical molecular glue degrader platform acquired by Novartis in 2024. Historically the closest direct competitor to Degron in novel-scaffold MGD discovery; now folded into a large pharma pipeline, representing both validation of the space and a competitive threat.

Broad incumbents

• Bristol Myers Squibb (CELMoDs): Major pharma with a significant molecular glue degrader franchise (CELMoDs such as iberdomide, mezigdomide) acquired via Celgene and developed across oncology. Represents the dominant incumbent in the MGD space against which Degron's differentiated scaffolds must compete.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights8 records

Customer concentration

• LinkedInlinkedin.com/company/degrontx

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds7 records

Investors27 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Degron Therapeutics